1. Clinical

Access Denied

Written by Posted on Less than 0 min read


Access Denied

You don’t have permission to access ” on this server.

Reference #18.2d6d3e17.1727698936.1028b8e0

Member since

More from Admin

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas

OSAKA, Japan, October 18, 2023, and CAMBRIDGE, Massachusetts, October 17, 2023 — Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based on […]
Written by
  1. Clinical

FDA Clears Investigational New Drug application for muscular dystrophy treatment

MINNEAPOLIS and ST. PAUL, Minn., July 17, 2024. Today, Myogenica, a University of Minnesota startup company, announced U.S. Food and Drug Administration approval for an Investigational New Drug (IND) application for MyoPAXon — an induced pluripotent stem cell-derived muscle stem cell product to regenerate skeletal muscle. A pending clinical trial would evaluate the safety, tolerability […]
Written by
  1. Clinical

Earning Rewards through Clinical Studies: Everything You Need to Know

Earning Rewards through Clinical Studies: Everything You Need to Know Clinical studies play a crucial role in advancing medical research and finding new treatments for various diseases and conditions. These studies require the participation of volunteers who are willing to contribute their time and effort to help scientific progress. In exchange for their participation, many […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Constructive Outcomes from Part 3 BouNDless Trial of Investigational ND0612 in Folks with Parkinson’s Illness Experiencing Motor Fluctuation

JERSEY CITY, N.J., March 18, 2024. Mitsubishi Tanabe Pharma America, Inc. (MTPA) in the present day introduced the publication of leads to The Lancet Neurology from the pivotal, Part 3 BouNDless trial (NCT04006210) evaluating the efficacy, security and tolerability of investigational ND0612 – a steady, 24 hours/day subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) – […]
Written by
  1. Clinical

Getting Paid for Your Participation: Exploring Clinical Studies

Participating in clinical studies not only allows you to contribute to medical advancements but also gives you the opportunity to earn some extra cash. Clinical studies are essential for the development of new medicines, treatments, and therapies. These studies need individuals from various backgrounds who are willing to be part of the research process. If […]
Written by
  1. Clinical

How Clinical Studies Drive Innovation in Healthcare

Clinical studies play a crucial role in driving innovation in healthcare. These studies, also known as clinical trials, are research investigations designed to answer specific questions about new treatments or therapies. They are an essential part of the research and development process, providing valuable insights that improve patient care and shape the future of medicine. […]
Written by
  1. Clinical

Alzheimer’s drug discovery foundation’s statement on FDA advisory committee’s endorsement of donanemab

NEW YORK, June 10, 2024. Today, the FDA Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that donanemab shows clinical benefit for the treatment of early Alzheimer’s disease. If approved, donanemab would become the second disease-modifying drug for Alzheimer’s to receive full approval, expanding the arsenal of available drugs needed to treat Alzheimer’s […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Clinical

Zibotentan/Dapagliflozin Combination Demonstrated Significant Albuminuria Reduction in Patients with Chronic Kidney Disease and Proteinuria in ZENITH-CKD Phase IIb Trial

November 3, 2023 — Combination of zibotentan with dapagliflozin showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), used to assess albuminuria, at 12 weeks compared with dapagliflozin alone. After 12 weeks of treatment, the Phase IIb ZENITH-CKD trial showed that the UACR difference of zibotentan/dapagliflozin versus dapagliflozin alone (n=177) was –33.7% […]
Written by
  1. Biology

Peering into the mind of artificial intelligence to make better antibiotics

DENVER, Aug. 18, 2024 — Artificial intelligence (AI) has exploded in popularity. It powers models that help us drive vehicles, proofread emails and even design new molecules for medications. But just like a human, it’s hard to read AI’s mind. Explainable AI (XAI), a subset of the technology, could help us do just that by […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Genetic tracing at the Huanan Seafood market further supports COVID animal origins

A new international collaborative study provides a list of the wildlife species present at the market from which SARS-CoV-2, the virus responsible for the COVID-19 pandemic, most likely arose in late 2019. The study is based on a new analysis of metatranscriptomic data released by the Chinese Center for Disease Control and Prevention (CDC). The […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Plant-derived secondary organic aerosols can act as mediators of plant-plant interactions

A new study published in Science reveals that plant-derived secondary organic aerosols (SOAs) can act as mediators of plant-plant interactions. This research was conducted through the cooperation of chemical ecologists, plant ecophysiologists and atmospheric physicists at the University of Eastern Finland. It is well known that plants release volatile organic compounds (VOCs) into the atmosphere […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Giant salamander-like creature was a top predator in the ice age before the dinosaurs

Forty million years before the first dinosaurs evolved, a ferocious predator lurked in swampy waters. Its skull alone was over two feet long. It lay in wait, its jaws open wide, preparing to clamp down its interlocking jaws on any prey unwise enough to swim past. Meet Gaiasia jennyae, the swamp creature with a toilet […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

High H5N1 influenza levels found in mice given raw milk from infected dairy cows

Mice administered raw milk samples from dairy cows infected with H5N1 influenza experienced high virus levels in their respiratory organs and lower virus levels in other vital organs, according to findings published in the New England Journal of Medicine. The results suggest that consumption of raw milk by animals poses a risk for H5N1 infection […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Number of fish species at risk of extinction fivefold higher than previous estimates, according to a new prediction

Researchers predict that 12.7% of marine teleost fish species are at risk of extinction, up fivefold from the International Union for Conservation of Nature’s prior estimate of 2.5%. Nicolas Loiseau and Nicolas Mouquet from the MARBEC Unit (the Marine Biodiversity, Exploitation and Conservation Unit) in Montpellier, France, and colleagues report these findings in a study […]
Written by
Scientists uncover new way viruses fight back against bacteria
  1. Life Sciences

Climate is most important factor in where mammals choose to live, study finds

While human activity has had a massive effect on the natural world, a new study from North Carolina State University finds that climate is still the most influential factor in determining where mammals can thrive. The work sheds light on how climate change will affect wildlife populations. Roland Kays, lead author of a paper on […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

Basilea Announces FDA Acceptance of New Drug Application for Antibiotic Ceftobiprole

Treatment for: Skin and Structure Infection Basilea Announces FDA Acceptance of New Drug Application for Antibiotic Ceftobiprole Seeking approval for Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP) Prescription Drug User Fee Act (PDUFA) goal date set for April 03, 2024 Allschwil, Switzerland, […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

FDA Approves Penbraya (meningococcal groups A, B, C, W and Y vaccine) for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

FDA Approves Penbraya (meningococcal groups A, B, C, W and Y vaccine) for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents NEW YORK–(BUSINESS WIRE) October 20, 2023 — Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Penbraya™ (meningococcal groups A, B, C, […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

New Indication for Motpoly XR (Lacosamide Extended-Release) Capsules for Primary Generalized Tonic-Clonic Seizures (Adjunctive Treatment)

Generic name: lacosamideTreatment for: Seizures New Indication for Motpoly XR New Indication for Motpoly XR (Lacosamide Extended-Release) Capsules for Primary Generalized Tonic-Clonic Seizures (Adjunctive Treatment) SILVER SPRING, MD. June 7, 2024/FDA Approvals/ — Today, the U.S. Food and Drug Administration (FDA) granted Aucta Pharmaceuticals a prior approval supplemental new drug application for the use of […]
Written by
Next
No Comments
Leave a comment Cancel
Comments to: Access Denied

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.